AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Prioritisation of foodborne pathogens === The Food and Agriculture Organization of the United Nations and The World Health Organization have published a global ranking of foodborne parasites using a multicriteria ranking tool concluding that Taenia solium was the most relevant, followed by Echinococcus granulosus, Echinococcus multilocularis, and Toxoplasma gondii. The same method was used regionally to rank the most important foodborne parasites in Europe ranking Echinococcus multilocularis of highest relevance, followed by Toxoplasma gondii and Trichinella spiralis.
Freeman's sole film release of 2010 was Red with co-stars Bruce Willis, Helen Mirren, and John Malkovich. Red is loosely adapted from the comic-book series Red, created by Warren Ellis and Cully Hamner and published by the DC Comics imprint Homage. Freeman plays CIA mentor Joe, who helps retired fellow agent Frank (Willis) to uncover some assassins. The film was a critical and commercial success; writing for Melbourne's The Age, Jim Schembri praised Freeman and the cast who "bring an infectious comic energy to their roles". Besides film, Freeman worked on other projects. In January 2010, he replaced Walter Cronkite as the voiceover introduction to the CBS Evening News presented by Katie Couric. CBS gave the need for consistency in introductions for regular news broadcasts and special reports as the basis for the change. Deborah Myers, head of Science Channel, approached Freeman to be the presenter of Through the Wormhole (2010–17). She had heard that he was "really interested in space and the universe", and the pair agreed to develop the series together. In 2011, Freeman narrated the fantasy Conan the Barbarian and appeared in the family drama Dolphin Tale, as prosthetic specialist Dr. McCarthy. Returning to theater in 2011, Freeman was featured with John Lithgow in the Broadway debut of Dustin Lance Black's play, 8, a staged reenactment of Perry v. Brown, the federal trial that overturned California's Proposition 8 ban on same-sex marriage. Freeman played Attorney David Boies.
=== Preface === The processing of different materials is determined by the origin of their species and substrate. While vegetable and fruit biomass-based textiles are formed into sheets, biotextiles made from proteins or bacterial cellulose are commonly drawn out during an extrusion and spun into a stronger thread. By cultivating plant and bacterial species on a determined substrate, it is possible to grow materials by harnessing their ability to digest and transform cellulose into natural composites. This process involves collecting them into proper scaffolds and executing physical and chemical treatment, so that these sheets of biomass visually resemble leather and exhibit comparable material and tactile properties. The processing of protein based textiles involves a variety of spinning techniques based on the type and quality that needs to be achieved.
Sources: en.wikipedia.org
== Predicting from DNA/RNA sequences == In biology, proteins are produced by translation of messenger RNA (mRNA) with the protein sequence deriving from the sequence of codons in the mRNA. The mRNA is itself formed by the transcription of genes and may be further modified. These processes are sufficiently understood to use computer algorithms to automate predictions of protein sequences from DNA sequences, such as from whole-genome DNA-sequencing projects, and have led to the generation of large databases of protein sequences such as UniProt. Predicted protein sequences are an important resource for protein identification by mass spectrometry. Historically, short protein sequences (10 to 15 residues) determined by Edman degradation were back-translated into DNA sequences that could be used as probes or primers to isolate molecular clones of the corresponding gene or complementary DNA. The sequence of the cloned DNA was then determined and used to deduce the full amino-acid sequence of the protein.
=== Relative biological effectiveness === After World War II, the concept of tolerance dose was replaced by that of maximum permissible dose and the concept of relative biological effectiveness was introduced. The limit was set in 1956 by the National Council on Radiation Protection & Measurements (NCRP) and the International Commission on Radiological Protection (ICRP) at 5 rem (50 mSv) per year for radiation workers and 0.5 rem per year for the general population. The unit Rem as a physical measure of radiation dose (from the English roentgen equivalent in man) was replaced by the unit Sv (sievert) in 1978. This was due to the advent of nuclear energy and its associated dangers. Prior to 1991, the equivalent dose was used both as a measure of dose and as a term for the body dose that determines the course and survival of radiation sickness. ICRP Publication 60 introduced the radiation weighting factor
Solvents can have a powerful effect on solubility, stability, and reaction rate. A change in solvent can also allow a chemist to influence the thermodynamic or kinetic control of the reaction. Reactions proceed at different rates in different solvents due to the change in charge distribution during a chemical transformation. Solvent effects may operate on the ground state and/or transition state structures. An example of the effect of solvent on organic reactions is seen in the comparison of SN1 and SN2 reactions. Solvent can also have a significant effect on the thermodynamic equilibrium of a system, for instance as in the case of keto-enol tautomerizations. In non-polar aprotic solvents, the enol form is strongly favored due to the formation of an intramolecular hydrogen-bond, while in polar aprotic solvents, such as methylene chloride, the enol form is less favored due to the interaction between the polar solvent and the polar diketone. In protic solvents, the equilibrium lies towards the keto form as the intramolecular hydrogen bond competes with hydrogen bonds originating from the solvent.
== Resistance == Diuretic resistance is defined as failure of diuretics to reduce fluid retention (can be measured by low urinary sodium) despite using the maximal dose of drugs. There are various causes for the resistance towards loop diuretics. After initial period of diuresis, there will be a period of "post-diuretic sodium retention" where the rate of sodium excretion does not reach as much as the initial diuresis period. Increase intake of sodium during this period will offset the amount of excreted sodium, and thus causing diuretic resistance. Prolonged usage of loop diuretics will also contributes to resistance through "braking phenomenon". This is the body physiological response to reduced extracellular fluid volume, where renin-angiotensin-aldosterone system will be activated which results in nephron remodelling. Nephron remodeling increases the number of distal convoluted cells, principle cells, and intercalated cells. These cells have sodium-chloride symporter at distal convoluted tubule, epithelial sodium channels, and chloride-bicarbonate exchanger pendrin. This will promote sodium reabsorption and fluid retention, causing diuretic resistance. Other factors includes gut edema which slows down the absorption of oral loop diuretics. Chronic kidney disease (CKD) reduces renal flow rate, reducing the delivery of diuretic molecules into the nephron, limiting sodium excretion and increasing sodium retention, causing diuretic resistance.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.